LONDON, Nov 14 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing ...

Novo Nordisk said Tuesday it will slash the list prices of several of its popular pre-filled insulin pens and vials by up to 75%, becoming the latest drugmaker to reduce the cost of the critical ...

Novo Nordisk (NVO) reportedly plans to phase out production of its human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. The Danish drugmaker ...

(Bloomberg) -- Novo Nordisk A/S’s decision to stop making insulin pens will narrow treatment options for children with diabetes unless non-patented drugmakers such as Biocon Ltd. step in to plug ...

Novo Nordisk plans to slash the U.S. list prices ... The company will also lower list prices of unbranded pre-filled insulin pens, vials of long-acting and short-acting insulin, and pre-mixed ...

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

Novo Nordisk and Sanofi—to immediately cut the prices of their insulin pens to $1 per device in LMICs, citing cost as a major barrier to pen adoption in less-wealthy nations.